Kreis 2003.

Methods	Study design: parallel RCT Study duration: not reported Duration of follow‐up: 2 years
Participants	Setting: multicentre Country: France 1st or 2nd kidney transplant recipients randomised week 8 post‐transplant Number: treatment group (78); control group (80) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group Early CsA reduction trough levels: 100 to 150 ng/mL (week 9 to 12), 75 to 100 ng/mL (week 12 to month 12), 75 ng/mL (months 12 to 24) Control group CsA reduction after 1 year: 150 to 200 ng/mL (week 9 to month 12) and 100 to 150 ng/mL (months 12 to 24) Both groups Daclizumab induction MMF: 2 g/d Steroids
Outcomes	SCr BPAR Graft survival Patient survival
Notes	Funding source: not reported Abstract‐only publications
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study was described as randomised, method of randomisation was not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to permit judgement